Acquisition strengthens access to clinically led virtual ADHD and mental health programs nationwide ...

Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more ...

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved or cleared by the FDA or by any other regulatory agency for any indication.

The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

MELBOURNE, Australia and INDIANAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare ...

MELBOURNE, Australia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that the United States Food and Drug Administration (FDA) has approved ...

By combining iron-replenishing and phosphate-binding mechanisms in a single oral drug, XOANACYL offers a multi-factor approach and has the potential to reduce treatment complexity, improve adherence ...

In preclinical tumor models, IMANs enhanced effector cell recruitment, resulting in increased tumor cell death. Additionally, they synergised with CAR-T cells to enhance tumor clearance in models of ...

From Swan Lake to The Nutcracker, ballet star shares the reality of living and dancing with hearing loss ...

Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support ...

The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial ...

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced it will release financial results for the third quarter 2025 ended September ...